Abstract

The centaur approach in drug discovery will be introduced to show how AI and drug hunters can work together to make better decisions. Results from current collaborations will illustrate how Exscientia is applying this approach to deliver an efficient drug discovery process and clinical candidates. In particular the presentation will focus on the current work Exscientia is undergoing with Evotec on immuno-oncology with the development of candidates as antagonist of A2AR and inhibitor of CD73. Using a combination of fragment screening and the AI platform, the project delivered molecules currently explored for candidate selection for A2AR and lead compounds for CD73.